

Syndax Pharmaceuticals

13:12 25 Sep 2018

Syndax's Entinostat in combination with Keytruda fails to meet endpoint in mid-stage trial for lung cancer

Shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) fell Tuesday after the biotech released disappointing updated results from its Phase 2 study dubbed ENCORE 601 that evaluated its lead product candidate Entinostat in combination with Merck & Co's (NYSE:MRK) Keytruda for treating non-small cell lung cancer patients previously treated with both chemotherapy and PD-(L)1 therapy.

At the time of data cut-off, there were seven confirmed partial responses among the overall population of 72 efficacy-evaluable patients, for a 10% objective response rate, a median duration of response of 5.3 months, and a median progression free survival of 2.8 months, the company said.

"The results did not meet the prespecified objective response rate endpoint. Six of the seven responders had low or negative PD-(L)1 expression at study entry," the company said in a statement.

The stock fell 5.4% to \$6.84 midday Tuesday.

READ: Merck shares pop as its Keytruda drug results power ahead of Bristol-Myers, Roche

"The observation of durable responses seen with the entinostat-pembrolizumab combination in NSCLC patients previously treated with both chemotherapy and PD-(L)1 therapy is an important result, and we look forward to more fully characterizing patient selection tools to identify those who are most likely to respond," said Syndax co-founder and Chief Scientific Officer Peter Ordentlich.

Syndax CEO Briggs Morrison said the company would communicate its plans for entinostat in this indication in the fourth quarter.

Separately, Syndax has already demonstrated that the delivery of entinostat in combination with hormone therapy can result in improvements in overall survival in advanced hormone receptor positive, or HR+, breast cancer patients, which has earlier led to Breakthrough Therapy Designation by the FDA for that indication.

The Waltham, Massachusetts clinical-stage biopharmaceutical company focuses on developing therapies for a range of cancers.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Price: 15.35

Market Cap: \$554.06 m

1 Year Share Price Graph



Share Information

Code: SNDX

Listing: NASDAQ

52 week	High	Low
	21.97	5.35

Sector: Medical technology & services

Website: www.syndax.com

Company Synopsis:

Syndax Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.